These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37065846)

  • 1. Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.
    Iorio A; MacDonald V; Caillaud A; Luckevich MD; Christoffersen P; Matino D; Keepanasseril A; Iserman E; Germini F; Bentley A; Poon MC
    Res Pract Thromb Haemost; 2023 Mar; 7(3):100106. PubMed ID: 37065846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study.
    Matino D; Iorio A; Keepanasseril A; Germini F; Caillaud A; Carcao M; Hews-Girard J; Iserman E; James P; Lee A; Phua CW; Sun HL; Teitel J; Poon MC
    Res Pract Thromb Haemost; 2022 Mar; 6(3):e12661. PubMed ID: 35386274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
    Chan AK; Alamelu J; Barnes C; Chuansumrit A; Garly ML; Meldgaard RM; Young G
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1101-1113. PubMed ID: 33134776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years.
    Walsh KS; Mrakotsky C; Carcao M; Chan AKC; Nielsen PH; Holst H; Shapiro K
    Res Pract Thromb Haemost; 2024 Feb; 8(2):102341. PubMed ID: 38516633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
    Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
    J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
    Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
    J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
    J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study.
    Simpson ML; Kulkarni R; Escuriola Ettingshausen C; Medom Meldgaard R; Cooper DL; Klamroth R
    J Blood Med; 2019; 10():391-398. PubMed ID: 32009825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
    Rosén P; Rosén S; Ezban M; Persson E
    J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.
    Escuriola Ettingshausen C; Hegemann I; Simpson ML; Cuker A; Kulkarni R; Pruthi RK; Garly ML; Meldgaard RM; Persson P; Klamroth R
    Res Pract Thromb Haemost; 2019 Apr; 3(2):268-276. PubMed ID: 31011711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GlycoPEGylated recombinant factor IX for hemophilia B in context.
    Santagostino E; Mancuso ME
    Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
    Ezban M; Hermit MB; Persson E
    Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
    Carcao M; Kearney S; Lu MY; Taki M; Rubens D; Shen C; Santagostino E
    Thromb Haemost; 2020 May; 120(5):737-746. PubMed ID: 32369845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High variability in Factor IX one-stage assay in samples spiked with nonacog beta pegol among different pairs of reagent/detection system.
    Duboscq C; Sueldo E; Rosa C; Zirpoli M; Ceresetto J; Baques A; Arias M
    Int J Lab Hematol; 2024 Feb; 46(1):128-134. PubMed ID: 37704365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of nonacog beta pegol during surgery in persons with hemophilia B: a case series.
    Phua CW; Matino D; Kühnöl CD; Hegemann I; Matsushita T
    Res Pract Thromb Haemost; 2023 Oct; 7(7):102208. PubMed ID: 38077810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
    Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
    J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.